Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 228-234, August 2010

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

  • Robert Bissonnette, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada
    • Corresponding Author InformationCorrespondence to: Robert Bissonnette, MD, Innovaderm Research Inc, 1851 Sherbrooke est, Bureau 502, Montreal, Quebec, H2K 4L5, Canada.
    • ,
  • Chantal Bolduc, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada
    • ,
  • Yves Poulin, MD, FRCPC

      Affiliations

    • Centre de Recherche Dermatologique du Québec Métropolitain, Quebec, Canada
    • ,
  • Lyn Guenther, MD, FRCPC

      Affiliations

    • Guenther Dermatology Research Centre, London, Ontario, Canada
    • ,
  • Charles W. Lynde, MD, FRCPC

      Affiliations

    • Lynderm Research, Markham, Ontario, Canada
    • ,
  • Catherine Maari, MD, FRCPC

      Affiliations

    • Innovaderm Research Inc, Montreal, Quebec, Canada

Accepted 25 August 2009. published online 24 May 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Innovaderm Research Inc and an investigator grant from Abbott Laboratories.

 Disclosure: Dr Bissonnette has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Celgene, Centocor, EMD Serono, Galderma, Isotechnika, Leo Pharma, MedImmune, Ortho Biotech, Pfizer, and Schering-Plough Canada. He has received compensation in the form of grants and/or honoraria from these companies. Dr Bolduc has been a speaker, consultant, investigator, or advisory board member for Leo Pharma, Abbott, Amgen-Wyeth, Centocor, MedImmune, and Schering-Plough Canada. She has received compensation in the form of grants and/or honoraria from these companies. Dr Guenther has been a speaker, consultant, investigator, and advisory board member for Abbott, Amgen, Astellas-Pharma, Centocor, EMD Serono, Leo Pharma, Ortho Biotech, Novartis, Schering-Plough, and Wyeth. Dr Lynde has acted as a speaker and consultant for Astellas-Pharma, EMD Serono, Schering-Plough Canada, Abbott, Leo Pharma, and Amgen and receives compensation in the form of grants and honoraria. Dr Maari has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Centocor, Galderma, MedImmune, Ortho Biotech, and Schering-Plough Canada. She has received compensation in the form of grants and/or honoraria from these companies. Dr Poulin has been a speaker, consultant, investigator, and/or advisory board member for Abbott, Amgen-Wyeth, Astellas-Pharma, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor, EMD Serono, Galderma, Ortho Biotech, and Schering-Plough Canada. He has received compensation in the form of grants and/or honoraria from these companies.

 Reprints not available from the authors.

PII: S0190-9622(09)01150-5

doi:10.1016/j.jaad.2009.08.040

Journal of the American Academy of Dermatology
Volume 63, Issue 2 , Pages 228-234, August 2010

Article Tools

* Image Usage & Resolution